These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 29290222)

  • 1. Efficient therapy of Pompe disease by an acid α-glucosidase conjugate.
    Park K
    J Control Release; 2018 Jan; 269():441-442. PubMed ID: 29290222
    [No Abstract]   [Full Text] [Related]  

  • 2. Low-frequency enzyme replacement therapy in late-onset Pompe disease.
    Lin DS; Chiang MF; Ho CS; Hsiao CD; Lin CY; Wang NL; Chuang CK; Huang YW; Chang PC; Liu HL
    Muscle Nerve; 2013 Apr; 47(4):612-3. PubMed ID: 23322609
    [No Abstract]   [Full Text] [Related]  

  • 3. Ptosis in Pompe disease: common genetic background in infantile and adult series.
    Ravaglia S; Bini P; Garaghani KS; Danesino C
    J Neuroophthalmol; 2010 Dec; 30(4):389-90. PubMed ID: 21107130
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term enzyme-replacement therapy (ERT) with alglucosidase alfa: Evolution of two siblings with juvenile late-onset Pompe disease.
    Rafael Bretón Martínez J; Martínez AC
    J Neurol Sci; 2015 Nov; 358(1-2):459-60. PubMed ID: 26279333
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficient therapy for refractory Pompe disease by mannose 6-phosphate analogue grafting on acid α-glucosidase.
    Basile I; Da Silva A; El Cheikh K; Godefroy A; Daurat M; Harmois A; Perez M; Caillaud C; Charbonné HV; Pau B; Gary-Bobo M; Morère A; Garcia M; Maynadier M
    J Control Release; 2018 Jan; 269():15-23. PubMed ID: 29108866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme replacement in Pompe disease with an alpha-glucosidase-low density lipoprotein complex.
    Williams JC; Murray AK
    Birth Defects Orig Artic Ser; 1980; 16(1):415-23. PubMed ID: 7004520
    [No Abstract]   [Full Text] [Related]  

  • 7. Improvement of bilateral ptosis on higher dose enzyme replacement therapy in Pompe disease.
    Yanovitch TL; Casey R; Banugaria SG; Kishnani PS
    J Neuroophthalmol; 2010 Jun; 30(2):165-6. PubMed ID: 20404746
    [No Abstract]   [Full Text] [Related]  

  • 8. Infantile Pompe disease: clinical and genetic characteristics with an experience of enzyme replacement therapy.
    Cho A; Kim SJ; Lim BC; Hwang H; Park JD; Kim GB; Jin DK; Lee J; Ki CS; Kim KJ; Hwang YS; Chae JH
    J Child Neurol; 2012 Mar; 27(3):319-24. PubMed ID: 21940687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice.
    Su J; Sherman A; Doerfler PA; Byrne BJ; Herzog RW; Daniell H
    Plant Biotechnol J; 2015 Oct; 13(8):1023-32. PubMed ID: 26053072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acid alpha-glucosidase deficiency (Pompe disease).
    Fukuda T; Roberts A; Plotz PH; Raben N
    Curr Neurol Neurosci Rep; 2007 Jan; 7(1):71-7. PubMed ID: 17217857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
    van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
    Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of Potent Mannose 6-Phosphate Analogues for the Functionalization of Lysosomal Enzymes To Improve the Treatment of Pompe Disease.
    El Cheikh K; Basile I; Da Silva A; Bernon C; Cérutti P; Salgues F; Perez M; Maynadier M; Gary-Bobo M; Caillaud C; Cérutti M; Garcia M; Morère A
    Angew Chem Int Ed Engl; 2016 Nov; 55(47):14774-14777. PubMed ID: 27774736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyaluronidase increases the biodistribution of acid alpha-1,4 glucosidase in the muscle of Pompe disease mice: an approach to enhance the efficacy of enzyme replacement therapy.
    Matalon R; Surendran S; Campbell GA; Michals-Matalon K; Tyring SK; Grady J; Cheng S; Kaye E
    Biochem Biophys Res Commun; 2006 Nov; 350(3):783-7. PubMed ID: 17027913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme replacement therapy for infantile Pompe disease during the critical period and identification of a novel mutation.
    But WM; Lee SH; Chan AO; Lau GT
    Hong Kong Med J; 2009 Dec; 15(6):474-7. PubMed ID: 19966354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Report of the first Brazilian infantile Pompe disease patient to be treated with recombinant human acid alpha-glucosidase.
    Pereira SJ; Berditchevisky CR; Marie SK
    J Pediatr (Rio J); 2008; 84(3):272-5. PubMed ID: 18535739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune modulation in Pompe disease treated with enzyme replacement therapy.
    Banugaria SG; Patel TT; Kishnani PS
    Expert Rev Clin Immunol; 2012 Aug; 8(6):497-9. PubMed ID: 22992140
    [No Abstract]   [Full Text] [Related]  

  • 17. Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy.
    Spiridigliozzi GA; Heller JH; Kishnani PS; Van der Ploeg AT; Ebbink BJ; Aarsen FK; van Gelder CM; Van den Hout JM
    Neurology; 2013 Mar; 80(12):1173. PubMed ID: 23509050
    [No Abstract]   [Full Text] [Related]  

  • 18. Alglucosidase alfa and Pompe disease: still going strong?
    Lipinski SE
    Mol Genet Metab; 2012 Nov; 107(3):245-6. PubMed ID: 23034445
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiac outcome in classic infantile Pompe disease after 13 years of treatment with recombinant human acid alpha-glucosidase.
    van Capelle CI; Poelman E; Frohn-Mulder IM; Koopman LP; van den Hout JMP; Régal L; Cools B; Helbing WA; van der Ploeg AT
    Int J Cardiol; 2018 Oct; 269():104-110. PubMed ID: 30049495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α.
    Kishnani P; Tarnopolsky M; Roberts M; Sivakumar K; Dasouki M; Dimachkie MM; Finanger E; Goker-Alpan O; Guter KA; Mozaffar T; Pervaiz MA; Laforet P; Levine T; Adera M; Lazauskas R; Sitaraman S; Khanna R; Benjamin E; Feng J; Flanagan JJ; Barth J; Barlow C; Lockhart DJ; Valenzano KJ; Boudes P; Johnson FK; Byrne B
    Mol Ther; 2017 May; 25(5):1199-1208. PubMed ID: 28341561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.